|
|
|
| Clinical Efficacy of Entecavir Combined with Silibinin in the Treatment of Hepatitis B Patients with Non-alcoholic Fatty Liver Disease and its Influence on Liver Function |
| ZHAI Yunfeng, LI Xiurong |
| General Hospital of YongMei Group,Yongcheng Henan 476600 |
|
|
|
|
Abstract 【Objectives】To investigate the clinical efficacy of entecavir combined with silibinin in the treatment of patients with viral hepatitis B (CHB) complicated with non-alcoholic fatty liver disease (NAFLD) and its impact on liver function. 【Methods】A total of 104 patients with CHB and NAFLD admitted to our hospital from June 2021 to January 2023 were selected and divided into the control group (treated with entecavir in addition to conventional treatment) and the observation group (treated with silibinin in addition to conventional treatment) according to the treatment method, with 52 patients in each group. Two groups were compared in terms of clinical efficacy, liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), tumor marker alpha fetoprotein (AFP)], liver fibrosis indicators [laminin (LN), type Ⅲ procollagen (PC-Ⅲ), type Ⅳ collagen (Ⅳ-C), hyaluronic acid (HA)], inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-κB)]. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, ALT, AST, and AFP levels in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The serum levels of LN, PC-Ⅲ,Ⅳ-C, and HA in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05); The serum levels of IL-6, TNF-α, and NF-κB in both groups were lower than before treatment, and the observation group was lower than the control group (P<0.05).【Conclusion】 The combination of entecavir and silibinin in the treatment of CHB patients with NAFLD can improve liver function, reduce inflammatory response, and alleviate the progression of liver fibrosis.
|
|
Received: 14 September 2023
|
|
|
|
|
|
[1] KAYESH M E H,KOHARA M,TSUKIYAMA-KOHARA K.Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B: an overview[J].Int J Mol Sci,2021,22(19):10462.
[2] TONG X,SONG Y,YIN S,et al.Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease[J].Chin Med J (Engl),2022,135(14):1653-1663.
[3] 贾婷,李俊义,张秀灵,等.恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究[J].实用肝脏病杂志,2022,25(4):488-491.
[4] 聂璐,苏成霞.穴位埋线联合水飞蓟宾对非酒精性脂肪性肝炎患者免疫失衡和炎症因子的影响[J].现代中西医结合杂志,2022,31(15):2138-2141.
[5] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂志,2019,35(12):2648-2669.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[7] 马丽,李淑敏,李洁.慢性乙肝患者血清甲状腺激素、HBV-DNA及血清钙的表达与病情严重程度的相关性[J].现代消化及介入诊疗,2021,26(11):1441-1444.
[8] 龙爽爽,姜伟,董亚楠,等.自拟消癖化痰颗粒联合水飞蓟宾胶囊治疗非酒精性脂肪性肝炎(痰湿内阻证)的临床研究[J].中医药导报,2022,28(2):66-70.
[9] 张圣江,周杨,柯淑红,等.五苓散加味联合水飞蓟宾对痰瘀互结型非酒精性脂肪性肝病患者肝功能、血脂和Th17/Treg平衡状态的影响[J].中西医结合肝病杂志,2021,31(8):691.
[10] 温庆杰.恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化效果分析[J].国际感染病学(电子版),2020,9(1):130-131.
[11] 刘皎皎,杨跃青,叶苗清,等.消脂护肝汤联合水飞蓟宾对非酒精性脂肪肝患者糖脂代谢水平及肝功能的影响[J].世界中西医结合杂志,2021,16(7):1177-1180.
[12] 刘俊平,郭新忠,李晓敏,等.水飞蓟宾胶囊对慢性HBV感染患者肝纤维化Wnt/β-catenin信号通路的影响[J].中华医院感染学杂志,2022,32(3):336-340.
[13] 叶苗青,薛敬东,李粉萍,等.化脂复肝颗粒对非酒精性脂肪肝TLR4/NF-κB通路及脂肪铁死亡的调控及机制研究[J].现代中西医结合杂志,2021,30(30):3307-3312.
[14] 苏正昌.恩替卡韦联合水飞蓟宾治疗乙肝肝硬化效果观察及对肝纤维化和微炎症状态的影响[J].白求恩医学杂志,2018,16(1):21-23. |
|
|
|
2024, Vol. 41 
